{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:39:18Z","timestamp":1777473558592,"version":"3.51.4"},"reference-count":29,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Data on the accuracy of response assessment 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography-computed tomography (PET-CT) following (chemo)radiotherapy in patients with oropharynx squamous cell carcinoma (OPSCC) is predominantly based on HPV-positive disease. There is a paucity of data for HPV-negative disease, which has a less favourable prognosis. Methods: 96 patients treated with (chemo)radiotherapy for HPV-negative OPSCC with baseline and response assessment FDG PET-CT between 2013\u20132020, were analysed. PET-CT response was classified as negative, equivocal, or positive based on qualitative reporting. PET-CT response categories were analysed with reference to clinicopathological outcomes. Test characteristics were evaluated, comparing negative results to equivocal and positive results together. Post-test probabilities were calculated separately for positive and equivocal or negative results. Results: Median follow-up was 26 months. The negative predictive value of a negative scan was 93.7 and 93.2%, respectively, for primary tumour and nodal disease. For a negative scan, the post-test probability was 0.06 for primary and 0.07 for nodal disease. The post-test probability of an equivocal scan was 0.51 and 0.72 for primary and lymph node, respectively. The post-test probability of a positive scan approached 1. For patients with\/without a negative scan, two-year overall survival and progression-free survival were 83% versus 30% and 79% versus 17% (p &lt; 0.001), respectively. Conclusion: The NPV of a negative response assessment PET-CT in HPV-negative OPSCC is high, supporting a strategy of clinical monitoring. Contrasting with the published literature for HPV-positive OPSCC, an equivocal response scan was associated with a moderate rate of residual disease.<\/jats:p>","DOI":"10.3390\/cancers14194680","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T21:23:27Z","timestamp":1664313807000},"page":"4680","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Accuracy of Response Assessment FDG PET-CT Post (Chemo)Radiotherapy in HPV Negative Oropharynx Squamous Cell Carcinoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Zsuzsanna","family":"Iyizoba-Ebozue","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Leeds Cancer Centre, Leeds LS9 7TF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Billingsley","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leeds Cancer Centre, Leeds LS9 7TF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2681-9922","authenticated-orcid":false,"given":"Russell","family":"Frood","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leeds Cancer Centre, Leeds LS9 7TF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriram","family":"Vaidyanathan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leeds Cancer Centre, Leeds LS9 7TF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-032X","authenticated-orcid":false,"given":"Andrew","family":"Scarsbrook","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leeds Cancer Centre, Leeds LS9 7TF, UK"},{"name":"Leeds Institute of Health Research, University of Leeds, Leeds LS2 9NL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-2826","authenticated-orcid":false,"given":"Robin J. D.","family":"Prestwich","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Leeds Cancer Centre, Leeds LS9 7TF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"American Joint Committee on Cancer (AJCC) (2018). TNM Classification of Malignant Tumours, Springer. [8th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1200\/JCO.2009.23.1670","article-title":"Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma","volume":"27","author":"Shi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1017\/S0022215116000505","article-title":"Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines","volume":"130","author":"Mehanna","year":"2016","journal-title":"J. Laryngol. Otol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/hed.24447","article-title":"ACR Appropriateness Criteria (R) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas","volume":"38","author":"Beitler","year":"2016","journal-title":"Head Neck"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","article-title":"PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer","volume":"374","author":"Mehanna","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Royal College of Physicians of Edinburgh, and Administration of Radioactive Substances Advisory Committee (2016). Evidence-based indications for the use of PET-CT in the United Kingdom. Clin. Radiol., 71, e171\u2013e188.","DOI":"10.1016\/j.crad.2016.05.001"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1017\/S0022215116000487","article-title":"Laryngeal cancer: United Kingdom National Multidisciplinary guidelines","volume":"130","author":"Jones","year":"2016","journal-title":"J. Laryngol. Otol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.oraloncology.2013.12.003","article-title":"Reliability of post-chemoradiotherapy F-18-FDG PET\/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer","volume":"50","author":"Vainshtein","year":"2014","journal-title":"Oral Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hed.21655","article-title":"Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy","volume":"33","author":"Porceddu","year":"2011","journal-title":"Head Neck"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20140592","DOI":"10.1259\/bjr.20140592","article-title":"Assessment of outcomes with delayed (18) F-FDG PET-CT response assessment in head and neck squamous cell carcinoma","volume":"88","author":"Slevin","year":"2015","journal-title":"Br. J. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00259-015-3290-4","article-title":"(18) F-FDG PET\/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma","volume":"43","author":"Bird","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/hed.25513","article-title":"(18) F-FDG PET\/CT for locoregional surveillance following definitive treatment of head and neck cancer: A meta-analysis of reported studies","volume":"41","author":"Wong","year":"2019","journal-title":"Head Neck"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.oraloncology.2019.08.011","article-title":"12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers","volume":"97","author":"Rulach","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1038\/s41598-020-60739-3","article-title":"Post-treatment FDG PET-CT in head and neck carcinoma: Comparative analysis of 4 qualitative interpretative criteria in a large patient cohort","volume":"10","author":"Zhong","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2020.03.032","article-title":"FDG-PET\/CT scan assessment of response 12 weeks post radical radiotherapy in oropharynx head and neck cancer: The impact of p16 status","volume":"148","author":"Urban","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105870","DOI":"10.1016\/j.oraloncology.2022.105870","article-title":"Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection","volume":"128","author":"Zhou","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.ijrobp.2018.06.031","article-title":"Significance of Negative Posttreatment 18-FDG PET\/CT Imaging in Patients With p16\/HPV-Positive Oropharyngeal Cancer","volume":"102","author":"Ng","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/cncr.25033","article-title":"Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience","volume":"116","author":"Singhi","year":"2010","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2017.10.016","article-title":"Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines","volume":"126","author":"Gregoire","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clon.2020.12.007","article-title":"Radiotherapy for Oropharyngeal Carcinoma With an Uninvolved Contralateral Neck: The Safety of Omission of Contralateral High Level II and Retropharyngeal Lymph Nodes From Elective Target Volumes","volume":"33","author":"Murray","year":"2021","journal-title":"Clin. Oncol. R Coll. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clon.2019.03.001","article-title":"Quality Assurance Peer Review of Head and Neck Contours in a Large Cancer Centre via a Weekly Meeting Approach","volume":"31","author":"Ramasamy","year":"2019","journal-title":"Clin. Oncol. R Coll. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1007\/s00330-019-06401-7","article-title":"Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma","volume":"30","author":"Prestwich","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clon.2018.11.036","article-title":"Accuracy of Response Assessment Positron Emission Tomography-Computed Tomography Following Definitive Radiotherapy Without Chemotherapy for Head and Neck Squamous Cell Carcinoma","volume":"31","author":"Arunsingh","year":"2019","journal-title":"Clin. Oncol. R Coll. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2013.08.049","article-title":"Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status","volume":"87","author":"Huang","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.oraloncology.2018.11.033","article-title":"Utility of a repeat PET\/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy","volume":"88","author":"Liu","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00259-016-3612-1","article-title":"Post-treatment PET\/CT and p16 status for predicting treatment outcomes in locally advanced head and neck cancer after definitive radiation","volume":"44","author":"Awan","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4680\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:39:48Z","timestamp":1760143188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":29,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194680"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194680","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}